Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab for AML in Remission
NCT02532231Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2015
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in acute myeloid leukemia (AML), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2015; status: completed.
02
Drugs
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02532231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02532231.